Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy
Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy. Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2019-07, Vol.33 (4), p.1249-1262 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1262 |
|---|---|
| container_issue | 4 |
| container_start_page | 1249 |
| container_title | In vivo (Athens) |
| container_volume | 33 |
| creator | Liaw, Chuang-Chi Liao, Tzu-Yao Tsui, Ke-Hung Juan, Yu-Hsiang |
| description | Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy.
Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions identified mainly on pre-therapy computed tomography (CT) scans, and iii) inpatient-administered chemotherapy of at least three cycles. Chemotherapy regimens included 5-fluorouracil, leucovorin, cisplatin, and gemcitabine.
A total of 139 cases were enrolled in this study. The overall objective response rate was 60% and the median survival time was 17 months. Eight-two (59%) patients had inflammation-related symptoms following the course of chemotherapy. Fifty-five (41%) patients survived more than two years. All patients exhibited various fibrosis formations. No patient experienced unfavorable metastatic conditions. Inflammation-related symptoms remained in 28 (51%) patients. We found that surgery, invasive procedures, and infection likely led to a rapid tumor progression.
Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits. |
| doi_str_mv | 10.21873/invivo.11597 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6689348</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2253832263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-4b4d53f0a0fa903fc85aa3aa34d097a68be4037ec15bfb8724eb2e026b0ba3dd3</originalsourceid><addsrcrecordid>eNpVkV1rFTEQhoMo9li99FZy6c3WfOxusjeCLn5Bi6Va9C7MZmd7IrvJaZI90H9v7GlLhYGBmWfemeEl5DVnJ4JrJd85v3f7cMJ506knZMNVxyvV1N1TsmGi0ZVu-O8j8iKlP4y1ijHxnBxJLjQTvN2Q3Y81lnmY6Uf0OLlMpxDpOWSHPif6y-UtPcMMKZeSpZcx5C3OrvA9ROt8WIBeoEW3d_6K9sFn59ewJnoGzmf04C3SfovLv7kIu5uX5NkEc8JXd_mYXH7-9LP_Wp1-__Kt_3BaWalVruqhHhs5MWATdExOVjcAskQ9sk5BqwesmVRoeTNMg1aixkEgE-3ABpDjKI_J-4Pubh0WHG15J8JsdtEtEG9MAGf-73i3NVdhb9pWd7LWReDtnUAM1yumbBaXLM4zeCwPGiEaqaUQrSxodUBtDClFnB7WcGZuXTIHl8ytS4V_8_i2B_reFvkXjYiTjw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2253832263</pqid></control><display><type>article</type><title>Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Liaw, Chuang-Chi ; Liao, Tzu-Yao ; Tsui, Ke-Hung ; Juan, Yu-Hsiang</creator><creatorcontrib>Liaw, Chuang-Chi ; Liao, Tzu-Yao ; Tsui, Ke-Hung ; Juan, Yu-Hsiang</creatorcontrib><description>Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy.
Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions identified mainly on pre-therapy computed tomography (CT) scans, and iii) inpatient-administered chemotherapy of at least three cycles. Chemotherapy regimens included 5-fluorouracil, leucovorin, cisplatin, and gemcitabine.
A total of 139 cases were enrolled in this study. The overall objective response rate was 60% and the median survival time was 17 months. Eight-two (59%) patients had inflammation-related symptoms following the course of chemotherapy. Fifty-five (41%) patients survived more than two years. All patients exhibited various fibrosis formations. No patient experienced unfavorable metastatic conditions. Inflammation-related symptoms remained in 28 (51%) patients. We found that surgery, invasive procedures, and infection likely led to a rapid tumor progression.
Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>DOI: 10.21873/invivo.11597</identifier><identifier>PMID: 31280216</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Female ; Follow-Up Studies ; Humans ; Maintenance Chemotherapy ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Survival Analysis ; Tomography, X-Ray Computed ; Treatment Outcome ; Urologic Neoplasms - diagnostic imaging ; Urologic Neoplasms - drug therapy ; Urologic Neoplasms - mortality ; Urologic Neoplasms - pathology</subject><ispartof>In vivo (Athens), 2019-07, Vol.33 (4), p.1249-1262</ispartof><rights>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright 2019, International Institute of Anticancer Research 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-4b4d53f0a0fa903fc85aa3aa34d097a68be4037ec15bfb8724eb2e026b0ba3dd3</citedby><orcidid>0000-0001-6833-9121</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689348/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689348/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31280216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liaw, Chuang-Chi</creatorcontrib><creatorcontrib>Liao, Tzu-Yao</creatorcontrib><creatorcontrib>Tsui, Ke-Hung</creatorcontrib><creatorcontrib>Juan, Yu-Hsiang</creatorcontrib><title>Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy.
Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions identified mainly on pre-therapy computed tomography (CT) scans, and iii) inpatient-administered chemotherapy of at least three cycles. Chemotherapy regimens included 5-fluorouracil, leucovorin, cisplatin, and gemcitabine.
A total of 139 cases were enrolled in this study. The overall objective response rate was 60% and the median survival time was 17 months. Eight-two (59%) patients had inflammation-related symptoms following the course of chemotherapy. Fifty-five (41%) patients survived more than two years. All patients exhibited various fibrosis formations. No patient experienced unfavorable metastatic conditions. Inflammation-related symptoms remained in 28 (51%) patients. We found that surgery, invasive procedures, and infection likely led to a rapid tumor progression.
Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Maintenance Chemotherapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Urologic Neoplasms - diagnostic imaging</subject><subject>Urologic Neoplasms - drug therapy</subject><subject>Urologic Neoplasms - mortality</subject><subject>Urologic Neoplasms - pathology</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV1rFTEQhoMo9li99FZy6c3WfOxusjeCLn5Bi6Va9C7MZmd7IrvJaZI90H9v7GlLhYGBmWfemeEl5DVnJ4JrJd85v3f7cMJ506knZMNVxyvV1N1TsmGi0ZVu-O8j8iKlP4y1ijHxnBxJLjQTvN2Q3Y81lnmY6Uf0OLlMpxDpOWSHPif6y-UtPcMMKZeSpZcx5C3OrvA9ROt8WIBeoEW3d_6K9sFn59ewJnoGzmf04C3SfovLv7kIu5uX5NkEc8JXd_mYXH7-9LP_Wp1-__Kt_3BaWalVruqhHhs5MWATdExOVjcAskQ9sk5BqwesmVRoeTNMg1aixkEgE-3ABpDjKI_J-4Pubh0WHG15J8JsdtEtEG9MAGf-73i3NVdhb9pWd7LWReDtnUAM1yumbBaXLM4zeCwPGiEaqaUQrSxodUBtDClFnB7WcGZuXTIHl8ytS4V_8_i2B_reFvkXjYiTjw</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Liaw, Chuang-Chi</creator><creator>Liao, Tzu-Yao</creator><creator>Tsui, Ke-Hung</creator><creator>Juan, Yu-Hsiang</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6833-9121</orcidid></search><sort><creationdate>20190701</creationdate><title>Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy</title><author>Liaw, Chuang-Chi ; Liao, Tzu-Yao ; Tsui, Ke-Hung ; Juan, Yu-Hsiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-4b4d53f0a0fa903fc85aa3aa34d097a68be4037ec15bfb8724eb2e026b0ba3dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Maintenance Chemotherapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Urologic Neoplasms - diagnostic imaging</topic><topic>Urologic Neoplasms - drug therapy</topic><topic>Urologic Neoplasms - mortality</topic><topic>Urologic Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liaw, Chuang-Chi</creatorcontrib><creatorcontrib>Liao, Tzu-Yao</creatorcontrib><creatorcontrib>Tsui, Ke-Hung</creatorcontrib><creatorcontrib>Juan, Yu-Hsiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liaw, Chuang-Chi</au><au>Liao, Tzu-Yao</au><au>Tsui, Ke-Hung</au><au>Juan, Yu-Hsiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>33</volume><issue>4</issue><spage>1249</spage><epage>1262</epage><pages>1249-1262</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy.
Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions identified mainly on pre-therapy computed tomography (CT) scans, and iii) inpatient-administered chemotherapy of at least three cycles. Chemotherapy regimens included 5-fluorouracil, leucovorin, cisplatin, and gemcitabine.
A total of 139 cases were enrolled in this study. The overall objective response rate was 60% and the median survival time was 17 months. Eight-two (59%) patients had inflammation-related symptoms following the course of chemotherapy. Fifty-five (41%) patients survived more than two years. All patients exhibited various fibrosis formations. No patient experienced unfavorable metastatic conditions. Inflammation-related symptoms remained in 28 (51%) patients. We found that surgery, invasive procedures, and infection likely led to a rapid tumor progression.
Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>31280216</pmid><doi>10.21873/invivo.11597</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-6833-9121</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2019-07, Vol.33 (4), p.1249-1262 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6689348 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Female Follow-Up Studies Humans Maintenance Chemotherapy Male Middle Aged Neoplasm Metastasis Neoplasm Staging Prognosis Survival Analysis Tomography, X-Ray Computed Treatment Outcome Urologic Neoplasms - diagnostic imaging Urologic Neoplasms - drug therapy Urologic Neoplasms - mortality Urologic Neoplasms - pathology |
| title | Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T08%3A13%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Benefit%20for%20Patients%20With%20Metastatic%20Urothelial%20Carcinoma%20Receiving%20Continuous%20Maintenance%20Chemotherapy&rft.jtitle=In%20vivo%20(Athens)&rft.au=Liaw,%20Chuang-Chi&rft.date=2019-07-01&rft.volume=33&rft.issue=4&rft.spage=1249&rft.epage=1262&rft.pages=1249-1262&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/10.21873/invivo.11597&rft_dat=%3Cproquest_pubme%3E2253832263%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2253832263&rft_id=info:pmid/31280216&rfr_iscdi=true |